 |
Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology
Dec 19, 2012
|
5.4 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and antibody expertise, today
announced that Amgen has licensed the exclusive right to use the
Company's maytansino...
|
|
ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
Dec 10, 2012
|
9.6 KB |
| |
Benefit seen in both lenalidomide-naïve and lenalidomide-refractory
multiple myeloma
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference
Dec 6, 2012
|
5.6 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced that Daniel Junius,
President and CEO, will present at the upcoming Oppenheimer 23rd...
|
|
ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
Dec 3, 2012
|
8.1 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and antibody expertise, today
announced that there will be clinical data presentations on two
compounds that utiliz...
|
|
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
Nov 26, 2012
|
8.4 KB |
| |
— Dr. Morris brings to the Company extensive experience
leading the successful development and registration of novel anticancer
compounds —
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therape...
|
|
ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application
Nov 6, 2012
|
5.9 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer products using its
Targeted Antibody Payload (TAP) technology and antibody expertise, today
announced that Genentech, a member of the Roche Group, has disclosed
that the U.S. Fo...
|
|
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Nov 5, 2012
|
6.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer therapeutics using
its antibody expertise and Targeted Antibody Payload (TAP) technology,
today announced that the following presentations by Company management
at upcoming inve...
|
|
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Oct 26, 2012
|
55.6 KB |
| |
Marketing applications submitted for trastuzumab emtansine (T-DM1)
in the US and Europe.
Meaningful clinical data expected to be reported in coming year —
for ImmunoGen compounds, T-DM1, and other partner compounds.
ImmunoGen well positioned to advance its who...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results
Oct 19, 2012
|
5.9 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer products using its
Targeted Antibody Payload (TAP) technology and antibody expertise, today
announced that the Company will host a conference call at 8:00 a.m. ET
on Friday, Oct...
|
|
ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial
Oct 1, 2012
|
10.0 KB |
| |
Trastuzumab emtansine reduced risk of death by 32% compared to the
standard-of-care treatment arm of the trial.
Findings being reported at the ESMO 2012 Congress (European Society of
Medical Oncology) and published in New England Journal of Medicine.
WALTH...
|
|
ImmunoGen, Inc. Announces Presentation of New IMGN901 Clinical Data
Sep 6, 2012
|
11.1 KB |
| |
Phase I evaluation presented established IMGN901 dose being used in
Phase II assessment — the NORTH trial — for first-line treatment of
small-cell lung cancer (SCLC).
IMGN901 able to be administered at full single-agent dose in
combination regimen assessed.
...
|
|
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Sep 4, 2012
|
6.1 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer therapeutics using its antibody
expertise and Targeted Antibody Payload (TAP) technology, today
announced that the following presentations by Company management at
upcoming investor...
|
|
ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial
Aug 27, 2012
|
8.9 KB |
| |
Trastuzumab emtansine significantly improved overall survival (OS) as
well as progression-free survival (PFS) in its lead Phase III trial,
EMILIA.
Separately, the marketing application for trastuzumab emtansine has
been submitted to the US FDA, and one is to be submitted shortly to
...
|
|
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2012 Financial Results and Provides Corporate Update and Fiscal Year 2013 Guidance
Aug 3, 2012
|
58.7 KB |
| |
Positive Phase III results with trastuzumab emtansine (T-DM1) were
presented in a plenary session at ASCO in June; Roche intends to use
these data to apply in 2012 for marketing approval of the compound for
the use evaluated.
ImmunoGen expects up to three additional partner compounds t...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2012 Financial Results
Jul 26, 2012
|
5.8 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer products using its antibody expertise and Targeted Antibody
Payload (TAP) technology, today announced that the Company will host a
conference call at 8:00 a.m. ET on Friday, August ...
|
|
ImmunoGen, Inc. Prices Public Offering of Common Stock
Jul 12, 2012
|
7.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN) announced today that it has priced an
underwritten public offering of 6.25 million shares of its common stock
at a price to the public of $16 per share. Gross proceeds are expected
to be approximately $100 million, before deducting the underwriting
...
|
|
ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock
Jul 11, 2012
|
6.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN) announced today that it intends to offer
for sale its common stock in an underwritten public offering. The
offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as t...
|
|
ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target
Jul 11, 2012
|
8.8 KB |
| |
— Folate receptor 1 (FOLR1)-targeting compound is second novel
ImmunoGen product candidate to enter clinic this year —
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer therapeutics using its antibody
...
|
|
ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419
Jun 4, 2012
|
8.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company, today announced the presentation of new clinical data for the
investigational compound, SAR3419, at the American Society of Clinical
Oncology (ASCO) annual meeting taking place in Chicago, IL. SAR3419 uses
...
|
|
ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer
Jun 3, 2012
|
8.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company with a proprietary Targeted Antibody Payload (TAP) technology,
today announced that Roche is implementing a "three-pronged approach" to
developing trastuzumab emtansine (T-DM1) for early stage HER2-positive
...
|
|
|
